Travere Therapeutics, Inc.

Healthcare

NASDAQ:TVTX · NASDAQ Global Market

Market Cap $4.84B Beta 1.14 P/E (TTM) -223.2

$52.04 +6.40%

+$3.13 today

52W Low $13.88High $52.72

Vol 2.38M · Avg 2.24M

EPS (TTM)-$0.23

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+258.90%

Period High

$52.04

Period Low

$14.09

Latest

$52.04

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Legend Biotech Corporation

NASDAQ:LEGN

$6.63B

Centessa Pharmaceuticals plc

NASDAQ:CNTA

$6.15B

Apogee Therapeutics, Inc.

NASDAQ:APGE

$5.47B

CG Oncology, Inc. Common stock

NASDAQ:CGON

$5.25B

Celcuity Inc.

NASDAQ:CELC

$4.32B

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

$4.11B

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

$2.67B

Disc Medicine, Inc.

NASDAQ:IRON

$2.60B

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

$2.40B

Ascentage Pharma Group International

NASDAQ:AAPG

$409.04M

What is the latest TVTX filing?

The latest filing shown is 8-K dated Jun 2, 2026.

How many recent filings does TVTX have?

Intrinsic Alpha currently shows 20 recent filings for TVTX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.